Edition:
India

Axovant Sciences Ltd (AXON.OQ)

AXON.OQ on NASDAQ Stock Exchange Global Select Market

2.41USD
22 Jun 2018
Change (% chg)

$-0.26 (-9.74%)
Prev Close
$2.67
Open
$2.72
Day's High
$2.72
Day's Low
$2.41
Volume
3,003,680
Avg. Vol
711,258
52-wk High
$27.93
52-wk Low
$1.02

Latest Key Developments (Source: Significant Developments)

Axovant Sciences Says Entered Sales Agreement With Cowen And Co
Saturday, 23 Jun 2018 

June 22 (Reuters) - Axovant Sciences Ltd ::AXOVANT SCIENCES LTD - ON JUNE 22, 2018, CO ENTERED INTO A SALES AGREEMENT WITH COWEN AND COMPANY, LLC - SEC FILING.AXOVANT SCIENCES LTD - AGREEMENT TO SELL CO'S COMMON SHARES HAVING AGGREGATE OFFERING PRICE OF UP TO $75 MILLION FROM TIME TO TIME.  Full Article

Axovant Says Gavin Corcoran, Chief Medical Officer Of Allergan, To Join Co As EVP Of R&D
Tuesday, 29 May 2018 

May 29 (Reuters) - Axovant Sciences Ltd ::AXOVANT STRENGTHENS MANAGEMENT TEAM AND COMPLETES ORGANIZATIONAL RESTRUCTURING IN PREPARATION FOR PIPELINE EXPANSION.AXOVANT SCIENCES LTD - AS PART OF RESTRUCTURING PLAN, INTERNAL HEADCOUNT HAS DECREASED BY APPROXIMATELY 43%.AXOVANT SCIENCES LTD - GAVIN CORCORAN, CURRENT CHIEF MEDICAL OFFICER OF ALLERGAN PLC, TO JOIN AXOVANT AS EVP OF RESEARCH AND DEVELOPMENT.  Full Article

BRIEF-Axovant Sciences Submitted Final Protocol With Statistical Analysis Plan To FDA For Dementia With Lewy Bodies Study
Thursday, 7 Dec 2017 

Corrects headline to say the final protocol was submitted for dementia with Lewy bodies study, not Parkinson's study:AXOVANT SCIENCES - SUBMITTED FINAL PROTOCOL WITH STATISTICAL ANALYSIS PLAN TO FDA DESIGNATES UNIFIED PARKINSON DISEASE RATING SCALE - PART III AS PRIMARY EFFICACY ENDPOINT.AXOVANT SCIENCES LTD SAYS SUBMITTED PROTOCOL THAT DESIGNATES ADAS-COG & CIBIC+ AS CO-SECONDARY ENDPOINTS FOR PHASE 2B HEADWAY STUDY - SEC FILING.  Full Article

Axovant announces second fiscal quarter results
Friday, 3 Nov 2017 

Nov 2 (Reuters) - Axovant Sciences Ltd :Axovant announces second fiscal quarter financial results and corporate updates.Q2 loss per share $0.64.Q2 earnings per share view $-0.55 -- Thomson Reuters I/B/E/S.Axovant Sciences Ltd - ‍Axovant held cash of $235.4 million at september 30, 2017​.  Full Article

Axovant sciences says exploring nelotanserin as treatment for Rem sleep behavior disorder
Monday, 13 Feb 2017 

Axovant Sciences Ltd : Axovant sciences announces preliminary results from interim analysis of phase 2 study testing investigational drug nelotanserin in Lewy body dementia patients . Axovant expects to initiate phase 3 program in second half of 2017 . Plans to expand study recruitment to further explore updrs findings and expects final results in mid-2017 . Axovant Sciences-in interim analysis, secondary endpoints did not demonstrate statistically significant differences for nelotanserin relative to placebo .Axovant Sciences-is exploring nelotanserin as a potential treatment for rem sleep behavior disorder (RBD) in patients with dementia with Lewy bodies.  Full Article

Axovant Sciences receives FDA fast-track designation for intepirdine
Monday, 26 Sep 2016 

Axovant Sciences Ltd :Axovant Sciences receives FDA fast-track designation for intepirdine as an investigational treatment for dementia with lewy bodies.  Full Article

Axovant Sciences posts Q1 loss per share of $0.38
Tuesday, 16 Aug 2016 

Axovant Sciences Ltd : Axovant sciences announces expansion of dementia pipeline and reports financial results for the first fiscal quarter ended June 30, 2016 . Q1 loss per share $0.38 . Q1 earnings per share view $-0.36 -- Thomson Reuters I/B/E/S . Axovant says Axovant and QAAM Pharmaceuticals (QAAM) have entered into an exclusive license agreement . Axovant says financial terms of transaction were not disclosed . Axovant plans to initiate clinical studies for RVT-103 shortly, with initial results expected in 2017 . Announces plan to develop RVT-103, a combination of Glycopyrrolate and Donepezil, as a potential treatment for patients with dementia .Axovant sciences ltd says axovant does not expect program to have a material effect on its use of cash in fiscal year ending March 31, 2017.  Full Article

BRIEF-Axovant Sciences Initiated Reduction In Its Workforce

* AXOVANT SCIENCES LTD - ‍ ON FEBRUARY 12, INITIATED A CORPORATE REALIGNMENT THAT INCLUDED A REDUCTION IN ITS WORKFORCE - SEC FILING